Get started
Author

Abi Vainstein‐Haras

Observed names: A Vainstein-Haras, Abi Vainstein-Haras, Vainstein-Haras, A., Vainstein-Haras, Abi
OpenAlex ID: A5060798513
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
2021 · Bruno Bockorny, Teresa Macarulla, et al. · Clinical Cancer Research · 92
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
2023 · Zachary D. Crees, Michael P. Rettig, et al. · Nature Medicine · 80
PDF
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43
PDF
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
2023 · Zachary D. Crees, Michael P. Rettig, et al. · Blood Advances · 16
PDF
The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses
2025 · Claudio Scuoppo, Rick Ramirez, et al. · Frontiers in Immunology · 10
Abstract 5332: ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action
2024 · Claudio Scuoppo, Karen Mendelson, et al. · Cancer Research · 3
Abstract LB016: Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin
2023 · Claudio Scuoppo, Lila Ghamsari, et al. · Cancer Research · 3
Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC)
2021 · Manuel Hidalgo, Teresa Macarulla, et al. · Cancer Research · 3
Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation
2026 · Enise Ceran, Sonia Jaramillo Segura, et al. · Blood · 1
Abstract B114: Clinical-stage Wnt/β-catenin antagonist peptide ST316, suppresses colorectal cancer tumor growth by promoting BCL9 degradation
2025 · Lila Ghamsari, Franco Abbate, et al. · Molecular Cancer Therapeutics · 1
P11.82.A TARGETING THE GLIOBLASTOMA MASTER REGULATOR C/EBPß: A PHARMACOKINETIC AND PHARMACODYNAMIC NEOADJUVANT STUDY OF ST101
2023 · F Iwamoto, O Al Dalahmah, et al. · Neuro-Oncology · 1
PDF
Abstract CT204: High cytotoxic T-cell or polymorphonuclear cell infiltrates in the tumor microenvironment correlate with responses to BL8040 plus pembrolizumab combination therapy in metastatic pancreatic tumors: Scientific correlates of a phase II clinical trial
2020 · Carmelia M. Noia Barreto, Debora A. Ledesma, et al. · Cancer Research · 1
Synergistic anti-tumor activity of EGFR inhibition and C/EBPβ antagonism in GBM
2026 · Julia Diehl, Claudio Scuoppo, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract CT156: ST316, a first in class β-catenin antagonist, demonstrates safety and efficacy in metastatic colorectal cancer (mCRC)
2026 · Anthony El-Khoueiry, Susanna V. Ulahannan, et al. · Cancer Research
Abstract 2440: Single-cell MRD profiling identifies CXCR4-high AML as a responder population to CXCR4 inhibition with Motixafortide
2026 · Enise Ceran, Sonia Jaramillo-Segura, et al. · Cancer Research
Abstract 4767: Targeted antagonism of the activator protein 1 transcription factor complex results in potent anti-tumor activity in HNSCC models
2026 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Abstract 5562: Antagonism of β-Catenin/BCL9 interaction suppresses polymorphonuclear myeloid-derived suppressor cell generation and maintenance
2026 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation : clinical trials and observations
2026 · Ceran, Enise, Jaramillo Segura, Sonia, et al. · Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt)
Abstract 839: The clinical C/EBPβ antagonist peptide lucicebtide synergizes with molecularly targeted therapies in GBM
2025 · Julia Diehl, Ricardo Ramirez, et al. · Cancer Research
Abstract 1415: FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models
2025 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Abstract 2361: An ex vivo organoid study to identify biomarkers of sensitivity to ST316, a clinical-stage β-catenin antagonist peptide
2025 · Franco Abbate, Lila Ghamsari, et al. · Cancer Research
Abstract 3275: Reprogramming of MDSCs by ST316, a clinical peptide antagonist of b-Catenin/BCL9, enhances anti-tumor immuno- and chemotherapy
2025 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Single-Cell MRD Profiling in AML Identifies CXCR4 Expression as a Predictor of Motixafortide Response: An Exploratory Analysis from the BLAST Trial
2025 · Ceran, E., Merbach, A. K., et al. · RWTH Publications (RWTH Aachen)
Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission
2024 · Enise Ceran, Anne Kathrin Merbach, et al. · Blood
PDF
Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms
2024 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Works count: 48
Citation count: 254
H-index: 5
I10-index: 5
Year
Topic
Type